Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
about
Making inroads into improving treatment of bacterial vaginosis - striving for long-term cureCandida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005Isolation, molecular identification, and antifungal susceptibility profiles of vaginal isolates of Candida species.Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases.The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective.Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists aGenital mycotic infections in patients with diabetes.Characterization of the vaginal micro- and mycobiome in asymptomatic reproductive-age Estonian women.Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013)Clinical characteristics of Turkish women with Candida krusei vaginitis and antifungal susceptibility of the C. krusei isolates.Candida krusei: biotechnological potentials and concerns about its safety.Guideline: vulvovaginal candidosis (AWMF 015/072), S2k (excluding chronic mucocutaneous candidosis).Biofilm-forming ability of Candida albicans is unlikely to contribute to high levels of oral yeast carriage in cases of human immunodeficiency virus infection.Prevalence and epidemiological characteristics of vaginal candidiasis in the UAE.Antifungal mechanisms supporting boric acid therapy of Candida vaginitis.Detection of Candida species in pregnant Chinese women with a molecular beacon method.
P2860
Q26798310-9B1F5513-B5E2-42A1-9CF0-1DBEC33FC657Q28260910-D623ECAB-13BE-4887-B7DE-8E83A158AE2BQ33645341-388F8C43-5CD7-42F5-8C3B-992D3E4914A2Q33859133-270821D9-8CC6-4F18-87B2-ED825A8C87BAQ34186380-81E86DC6-03D2-41C4-BED4-D0A83F7CA0EAQ34269717-5AC60C00-4E1F-4150-BF8B-9C312CF5F853Q34349532-9DBAA4CC-E579-41CF-B15A-1857113C8434Q34571154-2E47866E-A7E1-4E9A-B51A-5567EC68A35EQ36743194-14902642-186A-43D1-B4F9-B137D9DE1A5CQ37417391-69FE93BD-40D4-4F16-B4A4-076C9B9F3904Q38028552-141FEB3D-B327-4CAF-8B30-144AC29AD920Q39035805-92608557-9246-4847-BE5F-7531930B5527Q39789893-EF707DB9-4149-4969-B99E-7712F9C853DAQ44545925-0661682D-D032-43BC-874B-88D389F18E04Q46211946-350E6322-78F0-46D7-9AF6-E85203D2CAB0Q54231648-F5838AEE-02A7-4584-9AA0-EA780A44DCC0
P2860
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
@en
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
@nl
type
label
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
@en
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
@nl
prefLabel
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
@en
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
@nl
P2093
P2860
P356
P1476
Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy.
@en
P2093
Dina Boikov
Jack D Sobel
Jose A Vazquez
Pallavi Bhargava
Shivani Singh
P2860
P304
P356
10.1086/343826
P407
P577
2002-10-10T00:00:00Z